Sara M Mangsbo

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects
    Sara M Mangsbo
    Department of Oncology, Radiology and Clinical Immunology, Division of Clinical Immunology, Uppsala University, Uppsala, Sweden
    J Immunol 183:6724-32. 2009
  2. ncbi Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
    Sara M Mangsbo
    Uppsala University, Sweden
    J Immunother 33:225-35. 2010
  3. ncbi CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity
    Sara M Mangsbo
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Immunother 31:34-42. 2008
  4. ncbi AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial
    Per Uno Malmstrom
    Division of Urology, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 16:3279-87. 2010

Detail Information

Publications4

  1. ncbi Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects
    Sara M Mangsbo
    Department of Oncology, Radiology and Clinical Immunology, Division of Clinical Immunology, Uppsala University, Uppsala, Sweden
    J Immunol 183:6724-32. 2009
    ..Specific inhibition of C3 suppressed CpG 2006 uptake into monocytes indicating that C3 fragments are involved in CpG internalization. The interplay between complement and TLR9 signaling demonstrated herein warrants further investigation...
  2. ncbi Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
    Sara M Mangsbo
    Uppsala University, Sweden
    J Immunother 33:225-35. 2010
    ..Thus, the combination of CpG with CTLA-4 or PD-1 blockade improved long-term survival and led to increased levels of tumor-reactive T cells and reduced numbers of Tregs at the tumor site...
  3. ncbi CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity
    Sara M Mangsbo
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Immunother 31:34-42. 2008
    ..Taken together, our data suggest that CpGs are superior to BCG for bladder cancer immunotherapy. Thus, this potent new drug may be an attractive therapeutic alternative and should be evaluated in bladder cancer patients...
  4. ncbi AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial
    Per Uno Malmstrom
    Division of Urology, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 16:3279-87. 2010
    ..Immunostimulating gene therapy with adenoviral vectors expressing CD40 ligand (AdCD40L) has shown efficacy in tumor models. CD40 ligand stimulates systemic immunity and may be effective in local and invasive human disease...